Neurocrine Biosciences has introduced a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the leading VMAT2 inhibitor for treating adults with tardive dyskinesia and chorea associated with Huntington’s disease. This new…
Labcorp, a leading global life sciences company, has been recognized as a top employer for disability inclusion by achieving a perfect score of 100 on the 2024 Disability Equality Index®.…
A prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has once again been named a constituent of the FTSE4Good Index Series. This recognition, marking the fourth year in a…
BeiGene, a global oncology company, has announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Rosenberg will succeed Julia Wang, who is leaving to pursue other…
Today, argenx and Zai Lab announced that China’s National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) for efgartigimod alfa injection (subcutaneous) on July 16, 2024. This 1,000mg…
WuXi AppTec, a leading global provider of R&D and manufacturing services for the pharmaceutical and life sciences industries, has been named to the FTSE4Good Index Series for the second consecutive…
Merck, a leading science and technology company, plans to acquire Unity-SC, a provider of metrology and inspection instruments for the semiconductor industry. The deal includes an initial payment of €155…
Merck, a leader in science and technology, has announced the launch of its first GMP (Good Manufacturing Practices) compliant cell culture media (CCM) manufacturing line in China. The new facility,…
Bristol Myers Squibb today announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line treatment for…
Bristol Myers Squibb today announced the validation of its near-term and net-zero science-based targets by the Science Based Targets initiative (SBTi) as part of a mid-year update on its environmental…
Roche announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for treating diabetic macular edema (DME) and diabetic retinopathy (DR),…
Roche announced new, four-year data from the RHONE-X extension study today. The study met all primary endpoints, demonstrating that Vabysmo® (faricimab) was well tolerated in people with diabetic macular edema…